Latest Research And Development News

Life360, Inc. reported robust Q3 2025 financial results driven by subscription and partnership revenue growth, alongside a leadership transition and strategic capital moves. The company also announced a major acquisition to bolster its advertising platform.

BrainChip Holdings Ltd has launched a fully underwritten $35 million placement alongside a $2 million share purchase plan to fund the commercialization of its Akida 2.0 technology and new TENNs product development. The capital raise underscores the company’s commitment to expanding its footprint in the rapidly growing edge AI market.

Elixir Energy’s upcoming Lorelle-3 appraisal well in Queensland’s Taroom Trough has qualified for a substantial federal R&D tax incentive, covering nearly half of its drilling and testing costs. This financial boost underpins the company’s ambitious plans to validate a major gas play in 2026.

VEEM Limited has launched its most efficient marine propulsion system, the VEEM Extreme package, delivering up to 18.1% fuel savings and speed gains. Early trials with Manly Fast Ferries signal strong commercial interest.

Elixir Energy has received a $3.861 million R&D tax refund, providing crucial funding for its upcoming Taroom Trough appraisal drilling and production testing programs.

Mount Ridley Mines has appointed Allister Caird as CEO, bringing critical minerals expertise to accelerate its rare earth and gallium projects in Western Australia and expand US partnerships.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Inhalerx Limited tapped $247,000 from a $38.5 million funding facility to support its clinical trials, while reporting a $310,000 cash burn in operating activities for the September quarter.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

InFocus Group Holdings has launched two new strategic units targeting digital assets and iGaming, backed by a significant loan and guided by a newly formed advisory board featuring industry veterans.